Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple key product design/release-timing claims and several adverse-effect 'common side effects' statements are not supported by the provided FDA label excerpts, and at least one statement (manufacturer attribution) is absent from the label. Overall alignment is poor.
Category Scores
Accurate Statements
The generic name for Jornay PM is methylphenidate hydrochloride.
Supported by label description of active ingredient (11 DESCRIPTION).
Jornay PM is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD) in individuals aged 6 years and older.
Supported by indication and age (1 INDICATIONS AND USAGE).
Jornay PM is a central nervous system stimulant.
Supported by label description/mechanism characterization (11 DESCRIPTION; 12.1 Mechanism of Action).
Jornay PM may include growth suppression as a serious side effect.
Supported by growth suppression warning and discussion (5.7 Long-term Suppression of Growth in Pediatric Patients; 6 ADVERSE REACTIONS).
Unsupported Statements
Jornay PM uses a dual-pulse delivery system.
Delivery-system design ('dual-pulse') is not supported by the provided label excerpts.
Jornay PM releases an initial dose of methylphenidate in the morning.
The provided label excerpt describes delayed and extended-release coatings but does not substantiate morning-specific initial release timing.
Jornay PM releases a second dose in the afternoon.
Afternoon/second-dose timing is not supported by the provided label excerpts.
Jornay PM is designed to provide symptom control throughout the day and into the evening.
Evening-specific/throughout-the-day symptom-control design claim is not supported by the provided label excerpts.
Common side effects of Jornay PM can include decreased appetite.
The provided excerpts do not support phrasing that decreased appetite is a 'common side effect' for Jornay PM.
Common side effects of Jornay PM can include insomnia.
Not supported by the provided label excerpts as a 'common side effect'.
Common side effects of Jornay PM can include anxiety.
Not supported by the provided label excerpts as a 'common side effect'.
Common side effects of Jornay PM can include weight loss.
While weight loss is discussed in relation to pediatric adverse outcomes, the provided excerpts do not substantiate the claim as a generic 'common side effect' statement.
Common side effects of Jornay PM can include nausea.
Not supported by the provided label excerpts as a 'common side effect'.
Common side effects of Jornay PM can include headache.
Not supported by the provided label excerpts as a 'common side effect'.
Jornay PM is manufactured by Ironshore Pharmaceuticals.
Manufacturing/labeler attribution is not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Jornay PM releases a second dose in the afternoon.
Label Reference
11 DESCRIPTION (does not state afternoon second dose timing; only describes delayed release and extended release over the day).
Important Omissions
No evaluation/coverage of contraindications, boxed warning details, drug interactions, or comprehensive warnings/precautions content beyond the partial growth/cardiac/psychiatric risk statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported product release-timing/device claims and unsupported 'common side effect' statements may mislead about how the product works and what adverse effects are expected; growth suppression risk was otherwise correctly aligned with pediatric warning content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple key statements are not supported by the provided FDA label excerpts, especially delivery system and timing claims, and several adverse-effect statements framed as 'common side effects' without label support.
Suggested Improvement
Remove or rewrite unsupported delivery/timing and 'common side effects' claims to match the provided label wording and scope (e.g., describe delayed-release/extended-release coatings without asserting morning/afternoon second-dose behavior), and avoid manufacturer attribution unless present in the label. Ensure all safety sections (boxed warnings/contraindications/interactions/other warnings) are covered with correct label support.